1. A Platform for the Generation of Site-Specific Antibody–Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines
   Ruud G. E. Coumans et al, 2020, Bioconjugate Chemistry CrossRef
2. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors
   Geoffrey I. Shapiro et al, 2017, Investigational New Drugs CrossRef
3. Antibody-drug Conjugate Targets, Drugs, and Linkers
   Beverly A. Teicher et al, 2022, Current Cancer Drug Targets CrossRef
4. Preclinical Development of an anti-5T4 Antibody–Drug Conjugate: Pharmacokinetics in Mice, Rats, and NHP and Tumor/Tissue Distribution in Mice
   Mauricio Leal et al, 2015, Bioconjugate Chemistry CrossRef